Pharmaceutical, Clinical, Regulatory and Product Development Advisors
Mr. Thompson served as President and CEO of Ångstrom from 2002 to 2007. Prior to joining Ångstrom, Mr. Thompson served as President & CEO of Chimeric Therapies, Inc., President and Chief Operating Officer of Bio-Technology General Corp., President & CEO of Cytel Corporation, and he previously held several senior management positions at Syntex Corporation, including President of its U.S. operating unit. Mr. Thompson has a B.S. in Pharmacy from Kansas University and a J.D. from The George Washington University School of Law.
Michael H. Silverman, MD, FACP
Dr. Silverman directs Ångstrom’s clinical trial programs. He previously directed clinical trials at Sterling Winthrop and headed clinical research for early stage companies, Telor and Biopure. He also served as Deputy Therapeutic Area Head at Sandoz (now Novartis) Research Institute. Dr. Silverman worked for KPMG’s Pharmaceutical Strategy group, and then founded BioStrategics Consulting Ltd.
James A. Taylor, Ph.D.
Dr. Taylor was formerly a Senior Research Scientist and Regulatory Liaison Officer for Pfizer, Director of Drug Regulatory Affairs for ICI Pharmaceuticals (now AstraZeneca), Vice President of Regulatory Affairs for Carter-Wallace and Corporate Vice President and Chief Regulatory Officer for ImmunoGen, Inc. In 1992, Dr. Taylor founded Taylor Associates, a regulatory consulting firm before forming Merchant-Taylor International.
Ms. Lorenzen provides direction to the Company in development program planning and management. Ms. Lorenzen was formerly Vice President and Development Program Director at Syntex USA, Inc. and at Chugai Biopharmaceuticals, and Vice President, Business Development/Development Program Director at Cytel Corporation.
Frederick E. Reno, Ph.D.
Dr. Reno is a consultant in the area of preclinical toxicology of pharmaceutical agents. Following a 20 year career with Hazleton Laboratories (now Covance), he established a consulting practice in 1988 and has assisted both large and small companies with advice relating to preclinical assessments, and has managed the design and execution of toxicology programs that have resulted in numerous IND's and NDA's.
Scientific Advisors: Oncology
Nils Brünner, MD, DMSc
Nils Brünner is a professor in Pathobiology at the Royal Veterinary and Agriculture University, Copenhagen, Denmark and Adjunct Professor in Internal Medicine at Georgetown University, Washington DC. He has an extensive experience in translational cancer research with emphasize on animal models and tumor marker assay development, in particular assays measuring proteinases, their receptors and inhibitors. He has published extensively in the use of these markers in different cancer diseases. Professor Brünner advises the Company on preclinical and clinical issues with regard to the urokinase system.
Bruce Dezube, MD
Dr. Dezube is Associate Professor of Medicine, Harvard Medical School and Associate Director for Cancer Clinical Trials at Beth Israel Deaconess Medical Center (BIDMC). He is a prominent investigator in the fields of cancer and AIDS. He played a key role in the pivotal trials and the development of liposomal doxorubicin. He established the AIDS Oncology subunit at BIDMC, a major teaching affiliate of Harvard Medical School. Dr. Dezube is the national chair of two NIH protocols investigating the use of an MMP inhibitor and an angiogenesis inhibitor in Kaposi sarcoma. He has delivered over 200 lectures and seminars locally, nationally and internationally on topics pertaining to his area of focus.
Adrian L. Harris, BSc, MA, DPhil, FRCP
Dr. Harris is Professor of Clinical Oncology at Oxford University and Director of the Imperial Cancer Research Fund's Clinical Oncology Unit at the Institute of Molecular Medicine. He has performed leading research in tumor angiogenesis and is responsible for taking many new drugs into clinical trial. Dr. Harris advises the Company on its preclinical development programs and on its clinical trial protocols.
Gordon Rustin, MD
Professor Rustin is Director of Medical Oncology at Mount Vernon Hospital, which is the largest cancer center in the South of England. He has published widely on management of gynecological cancers and germ cell tumors and the use of tumor markers. He has developed response criteria on CA125, which are now increasingly used in Phase II trials of ovarian cancer. He has recently been the principal investigator of two trials of vascular targeting agents as well as several trials in ovarian cancer. He was awarded an Honorary Professorship by University College London in March 2001.
Scientific Advisors: Ophthalmology
Arup Das, MD, PhD
Dr. Arup Das is Associate Professor of Ophthalmology and Cell Biology & Physiology, and the Director of the Retina Service at the University of New Mexico School of Medicine, Albuquerque. He is distinguished for his work on ocular angiogenesis and proteinases. He serves on the editorial board of the journal, Investigative Ophthalmology and Visual Sciences. Dr. Das, a vitreo-retinal surgeon, advises Ångstrom on the preclinical and clinical studies in retinal and choroidal neovascularization.
William R. Freeman, MD
Dr. Freeman is Professor of Ophthalmology and Director of the Joan and Irwin Jacobs Retina Center at the University of California San Diego. He is an innovator in local ocular therapies and has published over 300 peer reviewed scientific articles in the field of retina disease. He is a member of the editorial board of several important ophthalmic journals, is the recipient of numerous research grant awards and is a practicing surgeon in addition to running his own laboratory.